Medical network, June 9, due to the different from the consumer market, enter the medicine circulation field, traditional giant and the progress is not smooth motion, may in the cold chain link takes the lead. "Even if you buy a few running companies and build a logistics warehouse, you will find it difficult to take advantage of experience and channels in a short period of time." 

 

▍ stock turf "fight" 

 

Previously, third-party logistics had already "targeted" the medical circulation. Such as exit China DHL express delivery market, recent high-profile announced to invest, the field of Chinese medicine logistics was established in Beijing and 2 domestic DHL life sciences and healthcare logistics center. 

 

The ministry of Commerce Department, deputy director of the market order Wang Weili previously at an industry conference, according to the China post, motion and UPS 3 companies have been entering the medical logistics market. By the end of 2014, the country had achieved 123 third-party logistics enterprises that had been issued by provincial drug monitoring departments for "verification of third party pharmaceutical logistics". 

 

In 2014, the company began to lay out the medical cold chain. Motion control in 2016 annual report, report the final, motion controlling cold 56 urban transport network coverage, and the surrounding area, including 59 food cold storage, food transportation lines, 71 2 medicine, cold storage, 12 main pharmaceutical, medicine, cold storage and transit depot operating area of 2.5 square meters, 497 sets of refrigerator car, including over 227 vehicles of GSP certification, the pharmaceutical industry customers are mainly pharm, sanofi, mindray, etc. 

 

Although the third-party content into the bureau of medicine circulation has its logistics advantages, but still need to face the cruel fact is that by the pharmaceutical industry particularity of "stock" competition. 

 

Dry RongFu reporter analysis into the 21st century economy, only 1.6 trillion yuan, the current domestic pharmaceutical circulation market and in November 2016 national many ministries jointly issued the "pharmaceutical industry development planning guide, according to the pharmaceutical industry growth at around 10%. "At present, the Chinese medicine, China resources and the drug are 35 percent of the pharmaceutical circulation, and by 2020 the three will be 50 percent." 

 

And the profit margin of medical circulation is low. A after the ministry of commerce official told reporter in the 21st century economy, medicine circulation profit margins in the 1% to 2%, the giant American pharmaceutical circulation of profit margin of 1.5% to 1.5%. The average profit margin in China's pharmaceutical industry is 1.6 per cent, according to Mr Gan, and China post, which has less than 1 per cent of the medical circulation sector, will lose money in a second. 

 

And suitable abundant medicine social logistics needs to face competitors including sinopharm, China resources of medicine, Shanghai pharma, kyushu giants such as national medicine distribution, as well as the regional leading enterprises, such as medicine, liuzhou east China pharmaceutical medicine, guangzhou, etc. 

 

"The biggest shortboard for shunfeng medicine is there is no terminal." Dry RongFu said. 

 

The state drug holding company has established a partnership with more than 96 percent of the country's three hospitals. Liuzhou medicine works with more than 2,000 upstream suppliers and operates more than 20,000 products. The lower reaches of the three grade hospital in guangxi area and 90 percent of the secondary hospital long-term cooperation. 

 

To that end, several brokerages are betting on liuzhou medicine. Tang aijin, a hang seng analyst, points out that pharmaceutical companies are experiencing "initial rapid development", "competitive integration" and "value-added services" in three stages. "According to the current company in the supply chain structure, the layout of the medicine circulation, equipment distribution, value-added services, liuzhou medicine is different from most of the enterprise, is from 'competition integration phase transition to value-added service period, strategic layout ahead of peers." 

 

Association of Chinese pharmaceutical business supply chain branch secretary-general Zhu Jianyun reporter also analysis into the 21st century economy, traditional medicine logistics with channels and for pharmaceutical logistics operation experience for many years, huge advantage, although the new entrants such as motion make traditional enterprises feel to be an outsider to move the concerns of the cheese, "but even bought several operating companies, self-built logistics warehouse, in the short term is difficult to on the experience and channel advantage". 

 

However, zhu said that shunfeng's intervention is also a good thing, which can enhance the sense of crisis and quality of traditional enterprises and make up for the lack of traditional enterprises. "It can also be a supplement to a partner or market segment, not just a competitor." 

 

▍ vaccine breakthrough opportunities? 

 

"Stock" bad cut cake, the medicine also seem to see the motion is not easy, from the current along abundant pharmaceutical business analysis, it should be more power in terms of the vaccine. 

 

Previously, the shandong illegal vaccine case had allowed the company to see business opportunities. No one in the country can cover the country's pharmaceutical cold chain carriers, which is trying to explore the high-end logistics market with huge distribution networks. 

 

Shandong illegal vaccine case broke out, the state council revised the regulations on the administration of circulation of vaccines and vaccination, strict management of circulation of vaccines, stop by borrowing qualifications and notes of illegal business call "ticket" behavior, and to establish a traceability system in the whole process of the vaccine from production to use, strengthen the storage, transportation, cold chain requirements, add CDC, vaccination units in the receiving link for the obligations of temperature monitoring and recording. 

 

The GSP new rules also stipulate that the operation of a vaccine or biological enterprise should be stored and transported in a refrigerated (frozen) storage and transportation facility that is suitable for operation scale and management variety. In the course of transportation, appropriate insulation or refrigerating measures shall be taken for the drugs that are required for temperature. Refrigerated vehicles and refrigerated (frozen) boxes used in vaccine transportation should be able to adjust and display the temperature automatically. The transport of medicines shall be completed within the prescribed time limit and shall not be used as the storage site for the drug. 

 

Kyushu through tianjin pharmaceutical company general manager to the 21st century economy Chen Yanwu reporter pointed out that the new GSP for pharmaceutical enterprise storage temperature and humidity real-time monitoring, cold-chain logistics and transportation put forward higher requirements, but the cold chain especially the medicine such as vaccines, blood products category, warehousing, transportation cost is very high, so many small exit. 

 

This is certainly an opportunity for shunfeng medicine. And in the field of vaccine, national medicine, medicine, such as giant intervention is not deep, because the vaccine and drug delivery is two independent system, the former more through health epidemic prevention station to the centers for disease control and prevention to patients, and the differences between the drug circulation. 

 

"Vaccine field there are a lot of miao dealers, so the former shandong vaccine case of those who are caught, industry is not standard, if the medicine in the field of vaccine could have some kind of motion, the industry is very good." Mr Gan points out. 

 

Told 21st century economic report more than the medicine circulation industry agree that vaccines or along abundant medicine major breakthrough, so the former chengdu goes well with sanofi abundant pharmaceutical co., LTD. Cooperation is favored. 

 

However, due to the special nature of the medical industry, even with the vaccine, shunfeng medicine still encounters "levels". "In Shanghai, Beijing, wuhan, chengdu, changchun institute of China's five major biological, belong in the group, and group belonging to Chinese medicine, in its still dominate distribution advantage." Dry RongFu said.